Fulgent Genetics, Inc. (FLGT) Tops Q2 EPS by 5c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/8/2026

1. MRVL
2. ZS
3. PENG
4. NVDA
5. STZ
6. MSFT
7. SPY
8. SKYD
9. RCKT
10. IBM

Go back to Fulgent Genetics, Inc. (FLGT) Tops Q2 EPS by 5c

Fulgent Genetics Reports Second Quarter 2022 Financial Results

August 4, 2022 4:05 PM EDT

Revenue totals $125.3 million Core Revenue grows 102% year-over-year to $45.3 million Raises full year core revenue outlook to $185 million from previously announced $180 million

TEMPLE CITY, Calif.--(BUSINESS WIRE)-- Fulgent Genetics, Inc. (NASDAQ: FLGT) (Fulgent Genetics, Fulgent, or the Company), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced financial results for its second quarter ended June 30, 2022.

Second Quarter 2022 Results:

Revenue of $125.3 million, versus $153.6 million in Q2 2021 Billable tests... More